MedWatch

Gubra CEO aims for more big pharma partnerships

If it were up to Gubra, more partnerships would follow in the trail of a major new collaboration agreement with Boehringer Ingelheim. However, the company is not planning to conduct clinical work itself, says the CEO.

Foto: Gubra PR

The Danish biotech company Gubra has reached an extremely lucrative agreement with the German pharma group Boehringer Ingelheim.

The collaboration may earn Gubra up to EUR 250 million (almost USD 300 million), something which could prove hugely important to the company.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier